176 results
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics plc
2 Aug 24
Approved for advanced MAGE-A4+synovial sarcoma in adults with certain HLA types who have received prior chemotherapy
7:00am
-Looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics plc
30 May 24
Entry into a Material Definitive Agreement
4:09pm
of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks
8-K
EX-99.1
lk07tn pcwl
15 May 24
Adaptimmune Reports Q1 2024 Financial and Business Updates
7:39am
8-K
EX-99.1
wmbn281 nuu
15 May 24
Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital
7:14am
8-K
EX-99.1
50m86p 50mbr
12 Apr 24
Company remains focused on launching afami-cel later this year with a PDUFA date of August 4th and developing its broader sarcoma franchise
8:05am
8-K
EX-99.1
efg0frjm27sz c7h0
6 Mar 24
Adaptimmune Reports Q4 /Full Year 2023 Financial Results and Business Updates
7:05am
8-K
EX-99.1
z2p2j1
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
8-K
EX-99.1
tchfucn9i
31 Jan 24
Other Events
5:07pm
8-K
EX-99.1
ep4gh3h6fie 68cbph
4 Jan 24
Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million – Presentation at JP Morgan Healthcare Conference
7:46am
8-K
EX-99.1
m8jtwl25x4 a8v18eewi
6 Dec 23
Other Events
7:13am
8-K
EX-99.1
whepqyy ce
8 Nov 23
Adaptimmune Reports Third Quarter Financial Results and Business Update
7:37am
8-K
EX-99.1
nexcwx5tqi
31 Oct 23
Adaptimmune Reports Positive Data with Lete-cel1 from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS
8:07am